Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study is a dataset published in BMJ (2021). On theSindex it has a DataRank of 2.2, placing it in the top 9.9% of the data-sharing corpus. It has been cited 71 times, with 47 citing works in its 1-hop citation network.
Ranks in the top 10% for downstream scientific impact
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.641
From this paper's citation signal
Citation Network Contribution
1.5
From 34 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 47 citers.
NLM NIH HHS
Grant: R01 LM006910
Medical Research Council
Grant: 1959917
Wellcome Trust
Grant: 214588/Z/18/Z
National Institute for Health Research (NIHR)
Grant: ACF-2014-13-015
Versus Arthritis
Grant: 21605
National Institute for Health Research (NIHR)
Grant: SRF-2018-11-ST2-004
Wellcome Trust
Grant: unidentified
unidentified
UK Research and Innovation
Grant: MR/N013468/1
DTP Bid Led by University of Oxford
UK Research and Innovation
Grant: MR/K501256/1
DTG 2013 & 2014
European Commission
Grant: 806968
European Health Data and Evidence Network
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease
Additional file 1 of Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease